New antibody aimed at ARDS shows promise in early trial

NCT ID NCT05938036

Ongoing Disease control Sponsor: Aqualung Therapeutics Corp. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a single dose of an antibody called ALT-100 in people with moderate to severe acute respiratory distress syndrome (ARDS), a life-threatening lung condition. The trial involves 15 hospitalized adults and compares the drug to a placebo. The main goal is to check safety, and researchers will also see if it helps patients breathe better and leave the hospital sooner.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ALT-100 monoclonal antibody
What this could lead to: If successful, this could point toward a new treatment for acute respiratory distress syndrome (ARDS) that reduces time on a ventilator and shortens hospital stays.
What could go wrong: This is a very early Phase 2a trial with only 15 participants, so results may not apply to all ARDS patients. The drug may not improve outcomes or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute respiratory distress syndrome adult acute respiratory distress syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)

Contacts and locations

Locations

Banner University of Arizona

Tucson, Arizona, 85721, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.